GB Patent

GB452238A — Process for purifying progesterone preparations

Assigned to BASF Schweiz AG · Expires 1936-08-19 · 90y expired

What this patent protects

The hydroxylated impurities are removed from crude progesterone preparations by treatment of the preparations with an acylating agent followed by separation of the portion which has entered into reaction from the non-esterified portion which contains the progesterone. Suitable ac…

USPTO Abstract

The hydroxylated impurities are removed from crude progesterone preparations by treatment of the preparations with an acylating agent followed by separation of the portion which has entered into reaction from the non-esterified portion which contains the progesterone. Suitable acylating agents which yield sparingly soluble esters with the oxyketones are benzoyl, nitrobenzoyl, dinitrobenzoyl, and phenylbenzoyl chlorides, phenylisocyanate, diphenylisocyanate, and phosgene. It is preferred, however, to use agents which in addition to the acylating group, contain a salt forming group or a group which can be transformed into a salt forming group such as phthalic and maleic acid anhydrides, oxybenzoic acid chlorides, chlorosulphonic acid, phosphorus oxychloride and alkyl-meta-phosphates. In examples: (1) a crude progesterone crystallisate is reacted with phthalic anhydride in an atmosphere of nitrogen, the aqueous solution extracted with ether, and the ether extract washed with hydrochloric acid and water. Evaporation of the ether and recrystallization of the product yields progesterone in two polymorphous forms. The hydroxylated compounds may also if desired be extracted from the aqueous solution; (2) a crude progesterone crystallisate is reacted with 2 : 4-dinitrobenzoyl chloride in quinoline solution, the product mixed with water, extracted with ether, and worked up to yield the two polymorphous forms as in example 1; (3) a progesterone crystallisate is reacted with phthalic anhydride in pyridine, and worked up as in example 1.

Drugs covered by this patent

Patent Metadata

Patent number
GB452238A
Jurisdiction
GB
Classification
Expires
1936-08-19
Drug substance claim
No
Drug product claim
No
Assignee
BASF Schweiz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.